Evidence Table 7. Benefits (KQ1 & 2) (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Healthy Developmenta. | School-Based Functioning | Quality of Life | Comparator Broadly Applicable  | Outcomes Broadly Applicable  |
| Ahrens, 20021NA | NR | NR | NR | Yes | No |
| Berger, 20072OTT | CDIS (range: 0-16), MeanPretreatment G1: 8.5 (SD=2.3)G2: 8.2 (SD=2.2)Within group change at post-treatment:G1: -1.7 (calculated)G2: 0.1 (calculated)Between group change at post-treatment: -1.8 (calculated)Between group ANOVA: F=132.62, df=1,140, p<0.001 | NR | NR | Yes | Yes |
| Berger, 20093ES-SL | CDIS (range: 7-35), MeanPretreatment G1: 11.29 (SD=3.9)G2: 12.05 (SD=4.7)Within group change at post-treatment:G1: -2.71 (calculated)G2: -0.26 (calculated)Between group change at post-treatment: -2.45 (calculated)Between group ANOVA: F=40.73, df=1,164, p<0.001 | NR | NR | Yes | Unsure |
| Berkowitz, 20114NA | NR | NR | NR | Yes | Yes |

Evidence Table 7. Benefits (KQ1 & 2) (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Healthy Developmenta. | School-Based Functioning | Quality of Life | Comparator Broadly Applicable  | Outcomes Broadly Applicable  |
| Catani, 20095NA | Pretreatment G1: 2.06 (SD=1.34)G2: 2.14 (SD=1.17)Within group change at post-treatment assessment: G1: -1.56 (calculated)G2: -1.34 (calculated)Within group change at 6 Mos.: G1: -1.62 (calculated)G2: -1.43 (calculated)Between group change at post-treatment assessment: -0.22 (calculated) Repeated measures ANOVA for time\*treatment interaction p=NSBetween group change at 6 Mos. assessment: -0.19 (calculated)Repeated measures ANOVA for time\*treatment interaction p=NS | NR | NR | No | Yes |
| Ford, 20126 TARGET | NR | NR | NR | Yes | Yes |
| Gelkopf, 20097ERASE-Stress | DPS (range: 7-35), MeanPretreatment G1: 12.6 (SD=3.7)G2: 12.7 (SD=4.2)Within group change at post-treatment:G1: -2.3 (calculated)G2: -0.3 (calculated)Between group change at post-treatment: -2.0 (calculated)Between group ANOVA: F=15.50, df=1,106, p<0.001 | NR | NR |  Yes | Yes |
| Goenjian, 1997;20058, 9NA; NA  | NR | NR | NR | Yes | Yes |

Evidence Table 7. Benefits (KQ1 & 2) (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Healthy Developmenta. | School-Based Functioning | Quality of Life | Comparator Broadly Applicable  | Outcomes Broadly Applicable  |
| Jaycox, 200910SSET | SDQ (range: NR), MeanParent Rated,Pretreatment:G1: 11.64 (SD=5.80)G2: 12.46 (SD=5.90)Within group change at post-treatment assessment:G1: -1.92 (calculated); d=-0.39G2: -1.16 (calculated); d=-0.28Between group difference at post-treatment assessment: -0.76 (calculated); d=-0.10; regression estimate for followup controlling for baseline=NR, t=-0.19, p=NS Teacher Rated: Pretreatment: G1: 11.33 (SD=7.87)G2: 8.59 (SD=7.37)Within group change at post-treatment assessment:G1: -1.05 (calculated); d=0.006G2: 0.71 (calculated); d=0.28Between group difference at postttreatment assessment: -0.34 (calculated); d=-0.28; regression estimate for followup controlling for baseline=NR, t=-1.22, p=NS | NR | NR | Yes | Yes |
| Kemp, 201011NA | General Functioning ScalePretreatment G1: 21.00 (SD=4.38)G2: 19.21 (SD=4.55)Within group change:G1: -1.27 (calculated)G2: -0.13 (calculated)Between group change (95% CI): -1.14 (calculated) p=NS | NR | NR  | Yes | No |
| Layne, 200812TGCT  | NR | NR | NR | Yes | Yes |

Evidence Table 7. Benefits (KQ1 & 2) (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Healthy Developmenta. | School-Based Functioning | Quality of Life | Comparator Broadly Applicable  | Outcomes Broadly Applicable  |
| Nugent, 201013NA | NR | NR | NR | Yes | Yes |
| Robbb, 201014NA | NR | NR | PQ-LES-Q (range: 0-17)Pretreatment G1: 49.6 (SD=9.5)G2: 49.5 (SD=10.4)Within group LS mean change LOCF:G1: 7.2 (SD=1.3)G2: 10.7 (SD=1.5)Between group LS mean change score difference LOCF 95% CI: 0.2, 6.8 p=0.037 | Yes | Yes |
| Robertd, 200816NA | NR | NR | NR | Yes | Yes |
| Salloume, 200817NA | NR | NR | NR | Yes | Yes |
| Salloum, 2012 18NA | MSPSS Pretreatment:G1: 48.03 (SD=8.49)G2: 45.53 (SD=6.88)Effect size at post-treatment assessment:G1: d=0.04G2: d=0.36Effect size at 3 Mos. assessment:G1: d=0.38G2: d=0.39Effect size at 12 Mos. assessment:G1: d=0.17G2: d=0.51Significant effect of time on perceived social support F(3,186)=3.28, p=0.022, but no significant effect found by time\*treatment | NA | NA | Yes | Yes |

Evidence Table 7. Benefits (KQ1 & 2) (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Healthy Developmenta. | School-Based Functioning | Quality of Life | Comparator Broadly Applicable  | Outcomes Broadly Applicable  |
| Smith, 200719NA | NR | NR | NR | Yes | Yes |
| Stallardf, 200625NA | NR | NR | NR | Yes | Yes |
| Stein, 200320NA | PSC (range: 0-70): parent-rated psychosocial dysfunctionPretreatment G1: 19.1 (9.4)G2: 16.2 (8.1)Within group change:G1: -6.6 (calculated)G2: 0.3 (calculated)Adjusted between group change (95% CI): -6.4 (-10.4, -2.3) | TCRS, teacher-rated learning problems (range: 6-30)Pretreatment G1: 13.8 (7.3)G2: 12.7 (7.0)Within group change:G1: -1.1 (calculated)G2: 0.6 (calculated)Adjusted between group change (95% CI): -1.1 (-2.9, 0.8)TCRS teacher-rated shyness/anxiousness (range: 6-30)Pretreatment G1: 10.2 (4.1)G2: 11.0 (5.1) Within group change:G1: -0.4 (calculated)G2: -0.4 (calculated)Adjusted between group change (95% CI): 0.1 (-1.5, 1.7)TCRS teacher-rated acting out problems (range: 6-30)Pretreatment G1: 11.3 (7.0)G2: 10.6 (5.5)Within group change:G1: -1.9 (calculated)G2: -0.4 (calculated)Adjusted between group change (95% CI): -1.0 (-2.5, 0.5) 6 Mos. Assessment Between-group difference change from baseline (95% CI): -0.9 (-2.6, 0.8)G1: -2.1G2: 0.1 | NR  | Yes | Yes |

Evidence Table 7. Benefits (KQ1 & 2) (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Healthy Developmenta. | School-Based Functioning | Quality of Life | Comparator Broadly Applicable  | Outcomes Broadly Applicable  |
| Tol, 2008; 201021, 22NA; NA | Child-reported functional Impairment (range: 10-40),g.Pretreatment G1: 18.03 (SD=5.61)G2: 17.90 (SD=5.39)Within group change at 1 week:G1: -3.30 (SD=5.52)G2: -1.11 (SD=4.98)Within group change at 6 Mos.:G1: -3.48 (SD=5.70)G2: -2.06 (SD=5.07)Between group difference at 1 week (95% CI): d=0.42 (0.22, 0.61)Between group difference at 6 Mos.: Mixed method regression analysis mean change difference adjusted for school mean (95% CI): -0.52 (-0.43, 1.46); d=0.26 (0.07, 0.46)Parent-reported functional impairment (range: 10-40)Pretreatment G1: 14.04 (SD=4.24)G2: 14.20 (SD=4.43)Within group change at 1 week:G1: -1.44 (SD=4.72)G2: -1.16 (SD=4.23)Within group change at 6 Mos.:G1: -2.03 (SD=4.71)G2: -1.48 (SD=4.69)Between group difference at 1 week(95% CI): d=0.10 (-0.09, 0.29)Between group difference at 6 Mos.: d=0.07 (-0.12, 0.26) | NR | NR |  Yes | Yes |

Evidence Table 7. Benefits (KQ1 & 2) (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Healthy Developmenta. | School-Based Functioning | Quality of Life | Comparator Broadly Applicable  | Outcomes Broadly Applicable  |
| Tol, 201223NA | SDQ, Pro-social behavior:PretreatmentG1: 8.21 (SD=1.82)G2: 8.34 (SD=1.72)Within group change at post-treatment:G1: NRG2: NRBetween group change at post-treatment: NRLGCM estimate (SE): 0.016 (0.052); p=NSFunctional impairment: Pretreatment:G1: 3.64 (SD=4.47)G2: 3.23 (SD=4.37)Within group change at post-treatment:G1: NRG2: NRBetween group change at post-treatment: NRLGCM estimate (SE): -0.036 (0.143); p=NS | NA | NA | Yes | Yes |
| Zehnder, 201024NA | NR | NR | NR | Yes | Yes |

Note: No eligible study reported on decreased suicidality in the context of KQ1 or KQ2.

a. Healthy development as an outcome included improvements in interpersonal/social functioning or signs of developmental regression.

b. Sertraline did not demonstrate efficacy compared with placebo.

c. No standardized scales used.

d. Placebo was statistically as effective as either Imipramine or Fluoxetine in treating symptoms of ASD.

e. Treatment satisfaction 1: "I learned more about grief and trauma reactions" (1-10, with 10 being highest); mean score at follow-up: 9.20. Treatment satisfaction 2: "I expressed my thoughts and feelings about what happened"; mean score at follow-up: 9.18. Treatment satisfaction 3: "On a scale from 1 to 10, how helpful was counseling for you?"; mean score at follow-up: 9.31.

f. Debriefing was no more effective than placebo group intervention, although both groups made significant improvements in PTSD symptoms.

g. Child's Report: contextually constructed 10-item checklist.

Abbreviations: CDIS = Child Diagnostic Interview Schedule; CI = confidence interval; d = effect size; df = degrees of freedom; DPS = DISC Predictive Scales; ERASE-Stress – Enhancing Resilience among Students Experiencing Stress; ES-SL = ERASE Stress Sri Lanka; G = group; LGCM = latent growth curve modeling; LOCF = last observation carried forward; LS = least-squares; Mos. = months; MSPSS = Multidimensional Scale of Perceived Social Support; NA = not applicable; NR = not reported; NS = not significant; OTT = Overshadowing the Threat of Terrorism; PSC = Pediatric Symptom Checklist; PQ-LES-Q = Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire; SD = standard deviation; SDQ = Strengths and Difficulties Questionnaire; SSET = Support for Students Exposed to Trauma; TARGET = Trauma Affect Regulation: Guide for Education and Therapy; TCRS = Teacher Child Rating Scale; TGCT = Trauma and Grief Component Therapy.